Colleen Kusy
Stock Analyst at Baird
(2.54)
# 3,380
Out of 5,182 analysts
52
Total ratings
36.96%
Success rate
5.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLYM Climb Bio | Maintains: Outperform | $9 → $12 | $6.56 | +82.93% | 2 | Mar 6, 2026 | |
| ARGX argenx SE | Maintains: Neutral | $858 → $867 | $746.75 | +16.10% | 2 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $105.43 | +49.86% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $35.21 | -3.44% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $40.41 | +28.68% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $8.49 | +182.69% | 5 | Oct 3, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $38.83 | +33.92% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $3.34 | +79.64% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $26.56 | +54.37% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.73 | +246.82% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $65 | $47.58 | +36.61% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $8.89 | +181.21% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $5.89 | +3,465.37% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $3.43 | +891.25% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $3.88 | +5,827.84% | 1 | Nov 2, 2021 |
Climb Bio
Mar 6, 2026
Maintains: Outperform
Price Target: $9 → $12
Current: $6.56
Upside: +82.93%
argenx SE
Feb 27, 2026
Maintains: Neutral
Price Target: $858 → $867
Current: $746.75
Upside: +16.10%
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $105.43
Upside: +49.86%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $35.21
Upside: -3.44%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $40.41
Upside: +28.68%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $8.49
Upside: +182.69%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $38.83
Upside: +33.92%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $3.34
Upside: +79.64%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $26.56
Upside: +54.37%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.73
Upside: +246.82%
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $47.58
Upside: +36.61%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $8.89
Upside: +181.21%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $5.89
Upside: +3,465.37%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $3.43
Upside: +891.25%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $3.88
Upside: +5,827.84%